<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/227C3B24-E8A5-4F31-B62A-F3B73D5C74D8"><gtr:id>227C3B24-E8A5-4F31-B62A-F3B73D5C74D8</gtr:id><gtr:name>LEO Pharma (including subsidiary Peplin Ltd)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1E0E310-885F-4DC7-B908-31AACD12FAFA"><gtr:id>C1E0E310-885F-4DC7-B908-31AACD12FAFA</gtr:id><gtr:name>Boehringer Ingelheim</gtr:name><gtr:address><gtr:line1>Corporate Division Communications</gtr:line1><gtr:line2>Binger Strasse 173</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/227C3B24-E8A5-4F31-B62A-F3B73D5C74D8"><gtr:id>227C3B24-E8A5-4F31-B62A-F3B73D5C74D8</gtr:id><gtr:name>LEO Pharma (including subsidiary Peplin Ltd)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1E0E310-885F-4DC7-B908-31AACD12FAFA"><gtr:id>C1E0E310-885F-4DC7-B908-31AACD12FAFA</gtr:id><gtr:name>Boehringer Ingelheim</gtr:name><gtr:address><gtr:line1>Corporate Division Communications</gtr:line1><gtr:line2>Binger Strasse 173</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/39EE3945-CDA5-4319-8051-46B34D3B9AA0"><gtr:id>39EE3945-CDA5-4319-8051-46B34D3B9AA0</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Ferguson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_15052"><gtr:id>43698AD9-FE59-46C0-B53C-4F25267E4E7C</gtr:id><gtr:title>Increasing the translational impact of drug discovery</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_15052</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills.&amp;nbsp; The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers? understanding of each other?s needs and capabilities.&amp;nbsp; This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ?entrepreneurs in residence? schemes.&amp;nbsp; Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.</gtr:technicalSummary><gtr:fund><gtr:end>2017-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>242368</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>LEO Pharma (including subsidiary Peplin Ltd)</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Collaboration Agreement with Leo Pharma</gtr:description><gtr:id>C7E2A4DF-985A-4331-BB90-2943B36F8695</gtr:id><gtr:impact>Application to MRC DPRP approved at stage 1 with a full application to be submitted by 15th March</gtr:impact><gtr:outcomeId>58bd3dd1ea09c4.97354247-1</gtr:outcomeId><gtr:partnerContribution>Leo Pharma has provided invaluable advice of the Dundee's dermatology portfolio including advice of target product profiles and formulation. Leo has also provided target validation data in support of a project that we wish to collaborate on.</gtr:partnerContribution><gtr:piContribution>A research collaboration agreement has been concluded with Leo Pharma and a joint advisory board established between the 2 parties. The DDU has presented projects being developed by the DDU has Leo Pharma has presented a number of projects that they would wish to forma collaboration round. One of this projects is now in development and an application submitted the MRC DPFS.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Research Collaboration Agreement with AstraZeneca</gtr:description><gtr:id>23CED2C1-CDA3-4926-BD98-6CBA040CBFF2</gtr:id><gtr:impact>A new diversity screen will be completed q1 2017</gtr:impact><gtr:outcomeId>58bd3fcae766d2.46344520-1</gtr:outcomeId><gtr:partnerContribution>AZ have provided diversity and fragment libraries to Dundee</gtr:partnerContribution><gtr:piContribution>Dundee presented a drug target that had been screened in the DDU in 2013. Confirmed hits were optimised but not further developable. We discussed with AZ a desire to screen against a different library to look for new start points</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Boehringer Ingelheim</gtr:collaboratingOrganisation><gtr:department>Animal Health</gtr:department><gtr:description>Research Collaboration Agreement with BI and University of Berlin</gtr:description><gtr:id>61BABF5F-5DC2-4840-8464-97C621C9052E</gtr:id><gtr:impact>New assays developed for parasitic diseases in animals</gtr:impact><gtr:outcomeId>58be9a08bc6440.95935309-1</gtr:outcomeId><gtr:partnerContribution>BI funded the salary cost for the postdoc</gtr:partnerContribution><gtr:piContribution>The DDU hosted a postdoc for 6 months and contributed overheads, consumables and staff time</gtr:piContribution><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BI Animal Heath visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>67D1A342-985E-47DB-BFF3-9F942187B4A1</gtr:id><gtr:impact>senior delegation from BI Animal Health visited in August 2016 to discuss collaboration. Decision have been delayed due to BI's asset swap with Sanofi</gtr:impact><gtr:outcomeId>58c02f7279a0c3.94100554</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit from Alexion</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A05601E0-A6B3-4D86-AF10-41F8EC5FF6BE</gtr:id><gtr:impact>Following an initial meeting at Bio International in June 2014 Alexion visited the DDU to discuss possible collaboration opportunities. They were interested in a project that was already partnered. Tis project has now been released so follow up discussion is planned.</gtr:impact><gtr:outcomeId>58bfd2be8a1c33.05816549</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Astex Therapeutics</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2C76D146-AF69-48B5-B70E-A5539D2C54ED</gtr:id><gtr:impact>Following initial contact at BioEurope in November 2015 Alexion visited the DDU and School of Life Sciences. A collaboration agreement is under discussion with Dr Miratul Muqit regarding a Parkinson's project. Astex will hire the post doc under their Sustaining Innovation Postdoctoral research programme. It will be a collaborative appointment between Astex and Miratul's lab.
The post doc will be based at Astex initially with travel to Dundee and the potential for a relocation to Dundee in the latter stages of the project. The agreement will be concluded once the post doc has been recruited.</gtr:impact><gtr:outcomeId>58bfd1eddd2368.92348067</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DDU @ 10 conference hosted at Dundee</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B7F37057-1B71-4FE0-A86E-9057F64E3A8D</gtr:id><gtr:impact>Dundee hosted a 3-day conference event to celebrate the 10th anniversary of the DDU. The event was by invitation externally and open to the investigators from the University of Dundee. Delegates included industry, academia, funding bodies and government ministers and associated organisations</gtr:impact><gtr:outcomeId>58be9e97846c34.65505782</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>https://www.dundee.ac.uk/news/2016/global-experts-celebrate-10th-anniversary-of-drug-discovery-unit.php</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit form J&amp;JI</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1C453EC4-0FC3-4729-910C-F28346375FD5</gtr:id><gtr:impact>J&amp;amp;JI recruited a new medicinal chemist who subsequently visited the DDU. J&amp;amp;J has reviewed 2 DDU projects under CDA but no further action taken</gtr:impact><gtr:outcomeId>58c02e6d881b93.51148030</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DDU sponsored a re-entering antibacterial research drug discovery summit event in Boston</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4D88CC74-0BD0-480B-8DC8-C9EB09071F08</gtr:id><gtr:impact>The DDU attended an anti-bacterial drug discovery summit in Boston in 2016 and had bespoke flyers made for addition to conference packs.</gtr:impact><gtr:outcomeId>58c03240f3ae74.92555825</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://antibacterialdrugdevelopmentsummit.com</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Merck interest in oncology target</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5718FA1D-2754-44DB-994D-7BF0DC63A6A2</gtr:id><gtr:impact>Merck visited the DDU with an interest in our Fan1 project in collaboration with Professor John Rouse. They have their own in-house programme and were information gathering rather than looking to partner</gtr:impact><gtr:outcomeId>58c02f0aeeb052.30967417</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DDU exhibited at Innovation in Pharma event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5E9AFB5C-2B8F-416B-B234-9AAB2C38C0C9</gtr:id><gtr:impact>The DDU exhibited at the 4th annual Open Innovation in Pharma event in Vienna in November 2016</gtr:impact><gtr:outcomeId>58c0313df06ec8.33438310</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>https://fleming.events/events/pharma/open-innovation-pharma-biotech-conference</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Maruc Evans R&amp;D scouting in pharma event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>65FFEAAE-F5A8-430F-B453-ED0F62F2AA3E</gtr:id><gtr:impact>Julie Brady presented at a Marcus Evans R&amp;amp;D Scouting in Pharma event and took part in a discussion panel.</gtr:impact><gtr:outcomeId>58c03027908646.39035286</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www.marcusevans-conferences-paneuropean.com/marcusevans-conferences-event-details.asp?EventID=23132#.WMAwFRhFlBw</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Eurofins visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FDEDC244-9A80-43A2-9A9A-4095B67BC51D</gtr:id><gtr:impact>A senior delegation from Eurofins visited in July 2017. The Dundee site has down sized and the company is looking for interactions with local industry and academia. The visit was coordinated by Scottish Enterprise</gtr:impact><gtr:outcomeId>58c0330ed120f2.04976885</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>the DDU performed assay development and screening in collaboration with newco HepaRegeniX. In 2016 HepaRegeniX exercised an option to acquire sole ownership of the research data and paid an option fee of &amp;pound;165,900</gtr:description><gtr:grantRef>MC_PC_15052</gtr:grantRef><gtr:id>07BF96E3-20AA-410B-9B0F-B6A9A90507FC</gtr:id><gtr:impact>Income of &amp;pound;165,900 to the University of Dundee</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58be9c383b0748.15176556</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>HepaRegeniX exercise option to acquire DDU compounds</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_15052</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>